Medical Licensing (MD/DO) · Independent exam preparation
AOBOG Obstetrics and Gynecology Primary Written Exam: Clinical Decision Guide Study Guide
Practise urgent obstetric decisions, gynecologic diagnosis, contraception, infertility evaluation, pelvic support treatment, and cancer risk through focused AOBOG written-exam drills.
By CertMedbry · Updated 19 October 2026
Practise recognizing obstetric emergencies, choosing appropriate diagnostic tests, interpreting reproductive hormones, and distinguishing cancer prevention from screening. This guide follows the five domains of the AOBOG Obstetrics and Gynecology Primary Written Exam outline accessed October 10, 2026. Its 60 concepts provide selective coverage; the official outline defines the full examination scope, including topics beyond this guide.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide cover?
It covers the officially named Obstetrics and Gynecology Primary Written Exam within AOBOG primary specialty certification. The pathway also includes an oral examination. After successful completion of the required examination components, AOBOG recommends certification to the AOA. This is specialist physician certification, rather than a general medical licensing examination.
AOBOG Primary Certification in Obstetrics & Gynecology · AOBOG Written Exam
How many questions are there, and how many are scored?
The official written-examination outline describes 225 multiple-choice questions. The cited examination evidence does not establish a separate scored-question and pretest-question breakdown.
What examination duration and question format are established?
The official written outline describes 225 multiple-choice questions over four hours. These details do not establish a total appointment duration, break schedule, or proctoring arrangement. The 20 questions in this guide are independent four-option learning drills.
What are the official written-examination domain weights?
The published ranges are Gynecology 28–32%; Reproductive Endocrinology and Infertility 7–11%; Urogynecology and Reconstructive Pelvic Surgery 5–9%; Gynecologic Oncology 8–12%; and Obstetrics and Maternal Fetal Medicine 42–46%. OMM/OPP appears in every category. These ranges describe the written outline and should not be assigned to the oral examination.
Which blueprint version and effective date apply?
This guide uses the current official written outline documented as accessed October 10, 2026. That outline displays no revision number or effective date. The separate recommended-reference page states that it was updated in October 2025; that is a reference-list update, not a blueprint effective date.
How does the oral examination differ?
The primary oral examination is a separate component using clinical case scenarios to assess evaluation, treatment risks and benefits, and osteopathic diagnosis. Its official page states that in-person administration resumed in 2025. These multiple-choice drills prepare written-examination reasoning and do not simulate oral case assessment.
How are the guide, questions, and flashcards distributed?
The 60 concepts comprise 18 Gynecology, 6 Reproductive Endocrinology and Infertility, 4 Urogynecology and Reconstructive Pelvic Surgery, 6 Gynecologic Oncology, and 26 Obstetrics and Maternal Fetal Medicine concepts. The questions and flashcards each use allocations of 6, 2, 1, 2, and 9, respectively. These approximate the published ranges while remaining selective.
How should clinical references be applied?
The official outline establishes examination scope. Clinical recommendations here are supported separately by the cited professional, public-health, and government references. U.S. recommendations are attributed to their issuing organizations; RCOG references support the specified clinical principles and do not establish U.S. examination logistics or local drug protocols.
This is independent CertMedbry preparation for a physician specialty board-certification written examination. AOBOG primary certification also includes a separate oral examination. These original learning materials are neither official examination questions nor a prediction of examination performance.
Outline used: Current official AOBOG Primary Written Exam web outline, accessed 2026-10-10; no revision number or effective date is stated. The workbook label identifies the broader primary certification pathway, which includes written and oral examinations. This MCQ preview maps specifically to the officially named Obstetrics and Gynecology Primary Written Exam and preserves the assigned slug. The separate recommended-reference list states 'Last updated: October 2025'; that date is not an effective date for the blueprint.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Gynecology28–32%
1.Why can chronic anovulation cause abnormal uterine bleeding?
Ovulation normally creates a corpus luteum that produces progesterone. When ovulation is absent, estrogen may stimulate the endometrium without regular progesterone opposition, producing persistent proliferation and irregular shedding. Prolonged exposure also increases endometrial hyperplasia and cancer risk. The discriminating pattern is irregular or widely spaced cycles followed by unpredictable bleeding, rather than assuming every heavy episode represents a structural lesion. Pregnancy and other causes still require consideration.
Apply it
A patient reports several months without menstruation followed by prolonged bleeding. After excluding pregnancy, connect the irregular cycle pattern with possible anovulation and assess endometrial risk rather than treating the bleeding pattern as proof of fibroids.
Common pitfall: Irregular bleeding does not establish a benign hormonal diagnosis. Persistent bleeding and substantial endometrial risk require evaluation even when anovulation provides a plausible explanation.
NCI: Endometrial Cancer Prevention (PDQ), Health Professional Version · ASRM: Current Evaluation of Amenorrhea—Committee Opinion (2024)
2.Why does postmenopausal bleeding require endometrial evaluation?
Postmenopausal bleeding may reflect benign disease, but it is also a common presenting feature of endometrial cancer. Evaluation must address the endometrium because cervical cytology samples a different anatomical site and cannot exclude an endometrial malignancy. Histologic examination establishes the cancer diagnosis. The key decision is to investigate the bleeding source rather than allowing a recent normal cervical screening result to substitute for assessment of the uterine cavity.
Apply it
A woman who stopped menstruating five years ago develops new spotting despite a recent normal cervical screening result. Explain why the reassuring cervical result does not resolve the bleeding and arrange evaluation directed at endometrial disease.
Common pitfall: Do not interpret light bleeding as clinically trivial. Bleeding volume does not reliably distinguish endometrial cancer from benign causes in a postmenopausal patient.
NCI: Endometrial Cancer Treatment (PDQ), Health Professional Version
3.Why is endometrial protection important with systemic menopausal estrogen?
Systemic estrogen stimulates endometrial proliferation. In a patient with an intact uterus, prolonged unopposed exposure increases endometrial cancer risk; adding an appropriate progestogen counteracts that stimulation. The relevant anatomical distinction is whether functioning endometrial tissue remains, rather than whether the patient still menstruates. Counseling should connect the proposed hormone regimen to uterine status and explain that symptom relief and endometrial protection address different treatment objectives.
Apply it
A patient with an intact uterus requests systemic estrogen for troublesome menopausal symptoms. Before choosing a regimen, explain why the prescription must also address endometrial protection rather than supplying estrogen alone for symptom control.
Common pitfall: Do not generalize the endometrial risks of unopposed systemic estrogen to every estrogen formulation or assume that adding progestogen removes all hormone-therapy risks.
NCI: Endometrial Cancer Prevention (PDQ), Health Professional Version
4.Which contraceptive distinction matters in migraine with aura?
The CDC U.S. Medical Eligibility Criteria classify combined hormonal contraception as category 4 in migraine with aura, indicating an unacceptable health risk. Estrogen-containing pills, patches, and rings share this classification. The important clue is a history of aura, including focal neurologic symptoms, rather than headache severity alone. Copper and levonorgestrel intrauterine devices and progestin-only methods do not share this migraine-with-aura restriction, although other conditions still affect eligibility.
Apply it
A patient describes recurrent visual zigzags before headaches and requests a combined contraceptive patch. Recognize the aura history, explain the estrogen-related eligibility concern, and discuss eligible alternatives that match her preferences and other medical conditions.
Common pitfall: Changing from a combined pill to a combined patch or ring does not remove the estrogen-related contraindication associated with migraine with aura.
CDC: Summary of U.S. Medical Eligibility Criteria for Contraceptive Use, 2024
5.How does early postpartum status affect estrogen-containing contraception?
Postpartum physiology increases venous thromboembolism risk, making timing a central contraceptive eligibility variable. Under the CDC criteria, combined hormonal contraception is category 4 during the first 21 days postpartum, whether or not the patient is breastfeeding. Later classifications depend on breastfeeding and additional thrombotic risk factors. The decision therefore requires days since delivery and relevant risk history, rather than applying the usual eligibility assessment for a nonpregnant patient.
Apply it
Ten days after delivery, a patient requests the combined pill she previously tolerated. Identify the early postpartum interval as the decisive new risk factor and discuss an appropriate alternative while planning reassessment as postpartum eligibility changes.
Common pitfall: Prior uncomplicated use of estrogen-containing contraception does not establish eligibility immediately after childbirth. Postpartum timing independently changes risk even in a young nonsmoker.
CDC: Summary of U.S. Medical Eligibility Criteria for Contraceptive Use, 2024
6.Which contraceptive options differ in current breast cancer?
For current breast cancer, the CDC criteria classify hormonal contraceptive methods, including the levonorgestrel intrauterine device, as category 4. The copper intrauterine device is category 1 for this condition. This distinction reflects concern about hormonal exposure in an active hormone-sensitive disease context. A locally delivered progestin remains a hormonal method; route of delivery does not automatically remove the relevant breast-cancer restriction when selecting an otherwise suitable contraceptive.
Apply it
A patient undergoing treatment for current breast cancer wants highly effective reversible contraception. Compare copper and levonorgestrel intrauterine devices using the breast-cancer eligibility classification, then assess the remaining clinical considerations and her preferences.
Common pitfall: Do not assume that low systemic hormone exposure makes a levonorgestrel intrauterine device equivalent to a copper device in a patient with current breast cancer.
CDC: Summary of U.S. Medical Eligibility Criteria for Contraceptive Use, 2024
7.When should pelvic inflammatory disease be treated presumptively?
The CDC recommends a low threshold for presumptive PID treatment in sexually active patients at risk for sexually transmitted infection who have pelvic or lower abdominal pain, no better explanation, and cervical motion, uterine, or adnexal tenderness. Requiring all three tenderness findings reduces sensitivity and may delay treatment. Fever, mucopurulent discharge, and laboratory evidence can increase diagnostic specificity, but their absence does not by itself eliminate PID.
Apply it
A sexually active patient has new pelvic pain and cervical motion tenderness without an alternative diagnosis. Although she is afebrile and infection testing is pending, recognize that the clinical threshold for presumptive treatment can already be met.
Common pitfall: A negative cervical gonorrhea or chlamydia test does not exclude upper genital tract infection. Waiting for microbiologic confirmation can delay clinically indicated treatment.
8.Which PID findings favor hospital-based management?
PID management depends on severity and whether safe outpatient treatment is feasible. CDC hospitalization criteria include pregnancy, tubo-ovarian abscess, severe illness or vomiting, inability to tolerate or follow an outpatient regimen, failure to improve with oral treatment, and inability to exclude a surgical emergency. These findings change the setting and intensity of care. A tubo-ovarian abscess is particularly important because infection has formed a complex collection rather than remaining uncomplicated pelvic inflammation.
Apply it
A patient treated for PID returns with persistent pain, vomiting, and an adnexal collection on imaging. Recognize the abscess and inability to tolerate oral therapy as reasons to escalate care rather than simply repeating outpatient instructions.
Common pitfall: Do not classify PID severity from fever alone. Abscess, pregnancy, treatment failure, or an unresolved surgical differential can justify hospitalization without a dramatic temperature elevation.
9.How do Amsel findings support bacterial vaginosis?
Bacterial vaginosis reflects vaginal microbial dysbiosis rather than a single invading pathogen. Amsel diagnosis requires at least three of four findings: homogeneous thin discharge, clue cells, vaginal pH above 4.5, and a fishy odor before or after potassium hydroxide is added. The pattern is more informative than discharge alone. CDC guidance supports BV molecular testing in symptomatic patients; its performance and clinical meaning are less established in asymptomatic patients.
Apply it
A patient reports vaginal odor and thin discharge. Examination shows pH 5.2 and microscopy demonstrates clue cells. Use the combined findings to support BV instead of choosing treatment solely from the presence of vaginal discharge.
Common pitfall: An elevated vaginal pH alone does not diagnose BV. Avoid treating a single nonspecific finding as equivalent to the required combination of diagnostic criteria.
10.How does chlamydia retesting differ from a test of cure?
Retesting approximately three months after chlamydia treatment looks primarily for reinfection. A test of cure instead asks whether the treated infection cleared. CDC guidance generally does not recommend routine test of cure in nonpregnant patients unless adherence, persistent symptoms, or reinfection is a concern. Pregnancy is different: a nucleic acid amplification test approximately four weeks after treatment is recommended. Testing too early can detect nonviable organisms and create misleading positive results.
Apply it
A nonpregnant patient completes chlamydia therapy, has no symptoms, and reports reliable adherence. Explain why routine immediate clearance testing is unnecessary while arranging repeat testing around three months to identify a possible new infection.
Common pitfall: Do not replace three-month retesting with an early negative result. Clearance of the original infection does not protect against reinfection from an untreated or new partner.
11.Why is partner management essential after chlamydia treatment?
Many post-treatment chlamydia infections result from reinfection rather than antibiotic failure. CDC guidance therefore includes evaluation and presumptive treatment of recent sex partners, with expedited partner therapy considered where legally permitted and appropriate. Patients should avoid sex until the recommended treatment interval is complete and partners have been treated. The decisive mechanism is interruption of the transmission cycle; treating only the patient leaves a predictable route back to infection.
Apply it
A patient with repeat chlamydia infection says her symptoms resolved after treatment, but her partner never sought care. Address partner treatment and the interval before resuming sex rather than assuming the initial antibiotic could not work.
Common pitfall: Symptom resolution in either partner does not establish eradication. Chlamydia can be asymptomatic, so partner management cannot depend on whether the partner reports discomfort.
12.What can HPV vaccination prevent after a prior HPV infection?
HPV vaccines prevent new infections with covered HPV types; they do not clear an established infection or treat existing dysplasia. Prior infection with one type does not mean a person has encountered every vaccine-covered type. Counseling should therefore separate potential prevention of future infection from treatment of current disease. Vaccination also does not replace indicated cervical screening, because protection is type-specific and does not reverse disease already present.
Apply it
A patient with a positive HPV result asks whether vaccination will make the next test negative. Explain the preventive purpose of vaccination and discuss eligibility while keeping evaluation of the current cervical finding on its own pathway.
Common pitfall: Do not promise viral clearance or lesion regression from vaccination. Equally, do not assume one prior HPV infection proves there can be no remaining preventive benefit.
13.Which patients meet USPSTF osteoporosis screening recommendations?
The January 2025 USPSTF recommendation supports osteoporosis screening in women aged 65 years or older and in younger postmenopausal women at increased fracture risk after clinical risk assessment. Screening aims to identify people who may benefit from fracture-prevention treatment before a fracture occurs. Age alone does not settle the decision for younger postmenopausal patients. The screening recommendation also should not replace diagnostic assessment in someone with a fragility fracture or another established indication.
Apply it
A 59-year-old postmenopausal patient has low body weight and a parental history of hip fracture. Assess her fracture risk to determine screening eligibility instead of automatically deferring every bone-density discussion until her sixty-fifth birthday.
Common pitfall: Do not apply a population screening rule as a reason to withhold diagnostic evaluation after a low-trauma fracture. Screening and evaluation of established disease are different decisions.
14.When does suspected ectopic pregnancy require emergency surgery?
A ruptured ectopic pregnancy can cause life-threatening intraperitoneal hemorrhage. Hemodynamic instability, collapse, substantial abdominal pain, or evidence of internal bleeding shifts management toward urgent resuscitation and surgical treatment. Serial hormone measurements and medical treatment are options for selected stable situations, not substitutes for hemorrhage control. The key discriminator is the patient's clinical condition; a relatively low pregnancy hormone concentration does not establish protection from rupture or major bleeding.
Apply it
A patient with a positive pregnancy test develops severe abdominal pain, shoulder-tip pain, hypotension, and free intraperitoneal fluid. Mobilize emergency care and surgical management rather than waiting for a second pregnancy hormone measurement to clarify the diagnosis.
Common pitfall: Do not let an apparently reassuring hormone value override shock or suspected internal bleeding. Rupture risk cannot be excluded by a single concentration.
15.How should a stable pregnancy of unknown location be interpreted?
A positive pregnancy test without an identified intrauterine or ectopic pregnancy on ultrasound describes a pregnancy of unknown location, not a final diagnosis. Possibilities include an early intrauterine pregnancy, a failing pregnancy, and ectopic pregnancy. In a stable patient, repeated assessment using symptoms, transvaginal ultrasound, and serial pregnancy hormone measurements helps establish the outcome. Changes in hormone concentration inform the assessment but do not independently identify where implantation occurred.
Apply it
A stable patient has a positive pregnancy test and an ultrasound showing no definite pregnancy location. Explain the uncertainty, arrange follow-up assessment, and give clear emergency return instructions instead of labeling the findings as a confirmed miscarriage.
Common pitfall: An empty uterus on an early scan is not synonymous with ectopic pregnancy. Conversely, falling hormone concentrations do not eliminate the need for clinical follow-up.
16.Why does methotrexate treatment for ectopic pregnancy require follow-up?
Methotrexate inhibits rapidly dividing trophoblastic tissue, allowing selected unruptured ectopic pregnancies to resolve without surgery. Selection depends on clinical stability, pregnancy findings, medical suitability, and reliable follow-up. Serial pregnancy hormone measurements are needed because response is not immediate and additional treatment may be required. The patient remains at risk of rupture during resolution. Worsening pain, collapse, or other concerning symptoms therefore require reassessment even after treatment has been administered.
Apply it
A stable patient receiving methotrexate asks whether one injection ends all monitoring. Explain the need for scheduled hormone testing and immediate reassessment for concerning symptoms, confirming that she can reliably access both follow-up and emergency care.
Common pitfall: Receiving methotrexate does not prove successful resolution or eliminate rupture risk. Do not treat discharge after medication as the end of the ectopic-pregnancy episode.
17.Why is bleeding during tamoxifen therapy a distinct warning sign?
Tamoxifen has tissue-specific estrogen effects: it antagonizes estrogen signaling in breast tissue but can stimulate the endometrium. Its breast-cancer benefit therefore does not imply protection against endometrial disease. New abnormal vaginal bleeding requires evaluation, particularly after menopause. The decisive clinical clue is bleeding in a patient with this exposure, rather than assuming that every treatment-associated symptom is harmless. Endometrial cancer diagnosis depends on assessment of endometrial tissue when indicated.
Apply it
A postmenopausal patient taking tamoxifen develops intermittent spotting and attributes it to her medication. Explain why the medication history increases the relevance of endometrial evaluation instead of providing reassurance that the bleeding can be ignored.
Common pitfall: Do not infer that an antiestrogenic breast effect means an antiestrogenic uterine effect. Tamoxifen's action differs by tissue, making that shortcut clinically misleading.
NCI: Endometrial Cancer Treatment (PDQ), Health Professional Version · NCI: Endometrial Cancer Prevention (PDQ), Health Professional Version
18.How does applied osteopathic reasoning distinguish a possible mechanical contribution to pelvic pain from an urgent visceral process?
AOA principles connect structure, function, and the whole person. Apply them by documenting which movements reproduce the patient's pain, how pain limits function, and whether examination findings match that pattern. Separately assess pregnancy status, bleeding, infection risk, and pelvic tenderness. Reproduction with movement supports investigating a mechanical contribution but does not establish the sole cause. Pelvic pain with STI risk and cervical motion, uterine, or adnexal tenderness can meet the CDC threshold for presumptive PID treatment even without fever.
Apply it
A patient has movement-related pelvic discomfort plus new discharge and cervical motion tenderness. Record the functional findings, but address the qualifying PID presentation rather than choosing manipulation as the initial explanation and treatment for all symptoms.
Common pitfall: A reproducible painful movement does not exclude infection or pregnancy-related disease. Identify the observed structural and functional findings without claiming an unproved causal diagnosis.
AOA: Tenets of Osteopathic Medicine · CDC: Pelvic Inflammatory Disease
Reproductive Endocrinology and Infertility7–11%
19.When should an infertility evaluation begin?
ASRM recommends evaluation after 12 months of regular unprotected intercourse when the female partner is younger than 35 and after six months at age 35 or older. More immediate evaluation may be appropriate above age 40. Evaluation should also begin without delay when a condition associated with infertility is known or suspected, such as irregular cycles or tubal disease. Age and clinical risk therefore modify the waiting interval rather than merely adding background information.
Apply it
A 37-year-old with regular cycles has attempted conception for seven months. Begin evaluation now rather than requiring another five months, and ask about factors that could have justified investigation even earlier in the course.
Common pitfall: The usual waiting intervals apply when there is no known reason for impaired fertility. Amenorrhea or suspected reproductive disease should not be managed by waiting out the calendar.
ASRM: Fertility Evaluation of Infertile Women—Committee Opinion (2021)
20.Why should infertility assessment evaluate both partners concurrently?
Infertility can arise from ovulatory dysfunction, impaired tubal or uterine factors, male factors, or combinations of causes. ASRM recommends parallel evaluation when a male partner contributes to conception, including reproductive history and at least one semen analysis at the outset. The female evaluation addresses ovulation and reproductive tract structure and patency as appropriate. Concurrent assessment reduces delay and prevents a normal menstrual history from being mistaken for proof that the entire couple's evaluation is normal.
Apply it
A couple has tried to conceive for 14 months, and the female partner reports regular cycles. Arrange semen assessment alongside her indicated reproductive evaluation rather than completing every female test before considering a male contribution.
Common pitfall: Regular menstruation does not establish tubal patency or normal semen parameters. Avoid a sequential approach that treats infertility as exclusively a female diagnosis.
ASRM: Fertility Evaluation of Infertile Women—Committee Opinion (2021)
21.When is serum progesterone most useful for confirming ovulation?
When progesterone testing is indicated, ASRM recommends sampling approximately one week before the expected next menstrual period rather than automatically on cycle day 21. Progesterone rises after ovulation because the corpus luteum produces it. A value above 3 ng/mL provides presumptive evidence of recent ovulation. Because secretion fluctuates substantially, a single concentration can support that ovulation occurred but cannot reliably grade luteal-phase quality or establish overall fertility.
Apply it
A patient with consistent 35-day cycles is scheduled for progesterone testing. Move the sample from a routine day-21 appointment to approximately day 28, linking the timing to her expected next period rather than a standard calendar template.
Common pitfall: A low value drawn too early can falsely suggest anovulation. Do not interpret a poorly timed sample as evidence of an intrinsic luteal disorder.
ASRM: Fertility Evaluation of Infertile Women—Committee Opinion (2021)
22.How do initial laboratory tests organize secondary amenorrhea?
Pregnancy must be excluded first because it changes both interpretation and management. Initial amenorrhea assessment commonly includes thyroid-stimulating hormone, prolactin, and gonadotropin assessment, interpreted with estradiol and clinical findings. Elevated FSH with low estradiol suggests impaired ovarian function, whereas low or inappropriately normal gonadotropins with low estradiol suggest a hypothalamic or pituitary process. The mechanism matters: absent bleeding is a shared endpoint of several distinct disruptions in reproductive signaling.
Apply it
A patient with previously regular cycles develops amenorrhea. After pregnancy testing, use her history and hormone pattern to distinguish ovarian dysfunction from central suppression rather than prescribing a cycle-inducing treatment before considering the underlying mechanism.
Common pitfall: Amenorrhea is a symptom, not a single endocrine diagnosis. A normal-range gonadotropin can be inappropriate when estradiol is low and should be interpreted in context.
ASRM: Current Evaluation of Amenorrhea—Committee Opinion (2024)
23.Which hormone pattern suggests functional hypothalamic amenorrhea?
Functional hypothalamic amenorrhea results from reduced hypothalamic stimulation of the reproductive axis, often in association with energy deficit, substantial exercise, weight loss, or psychological stress. Estradiol is low, while FSH and LH are low or inappropriately normal; LH may be particularly suppressed. The pattern differs from ovarian insufficiency, in which reduced ovarian feedback produces elevated FSH. Diagnosis requires consideration of other causes rather than assuming exercise alone proves a functional disorder.
Apply it
A runner develops amenorrhea after increased training and weight loss. Pregnancy testing is negative, estradiol is low, and gonadotropins are not elevated. Connect the energy-history clues with central suppression while assessing nutrition, stress, and competing causes.
Common pitfall: Do not diagnose ovarian insufficiency solely from low estradiol. The direction of FSH response helps distinguish impaired ovarian function from reduced hypothalamic-pituitary stimulation.
ASRM: Current Evaluation of Amenorrhea—Committee Opinion (2024)
24.How do pubertal development and uterine anatomy guide primary amenorrhea evaluation?
Primary amenorrhea assessment considers whether secondary sexual development has occurred and whether a uterus and patent outflow tract are present. Breast development suggests estrogen exposure, while absent development redirects attention toward gonadal or central hormonal causes. A patient with breast development but no uterus requires a different differential from one with a uterus and absent estrogenization. ASRM supports evaluation when menstruation has not begun by age 15 despite otherwise normal secondary sexual development.
Apply it
A 16-year-old has normal breast development but has never menstruated. Include assessment of uterine anatomy early, using the combination of estrogenization and anatomy to organize the differential rather than ordering an undirected panel of every reproductive hormone.
Common pitfall: Normal breast development does not establish normal uterine anatomy or an unobstructed outflow tract. Hormonal maturation and the anatomical route for menstruation must be assessed separately.
ASRM: Current Evaluation of Amenorrhea—Committee Opinion (2024)
Urogynecology and Reconstructive Pelvic Surgery5–9%
25.Which symptom distinguishes stress from urgency urinary incontinence?
Stress urinary incontinence causes leakage with physical pressure events such as coughing, sneezing, laughing, or exercise. Urgency incontinence involves leakage associated with a sudden compelling need to urinate. These symptom mechanisms guide initial management and can coexist as mixed incontinence. The decisive detail is what immediately precedes leakage, rather than the amount leaked or the patient's age. A careful description of individual episodes is therefore more informative than the general label of bladder weakness.
Apply it
A patient reports one episode of leakage while coughing and separate episodes while rushing to the toilet. Identify features of mixed incontinence and determine which pattern is most bothersome before selecting the initial behavioral treatment emphasis.
Common pitfall: Do not classify every postpartum leak as stress incontinence. An urgent sensation before leakage identifies a different symptom mechanism even when pelvic floor risk factors are present.
26.Why can urinary retention present as leakage?
Overflow incontinence occurs when the bladder does not empty adequately and urine leaks from an overfilled reservoir. Associated clues include difficulty initiating urination, a weak stream, incomplete emptying, or frequent small leaks. This differs from a normally emptying bladder that leaks during coughing or an episode of urgency. The decision is to investigate impaired emptying and its cause instead of reflexively applying treatment intended to reduce bladder activity.
Apply it
A patient describes persistent dribbling, a weak stream, and the feeling that urination never empties her bladder. Assess emptying and potential retention causes rather than assuming that frequent leakage automatically represents an overactive bladder.
Common pitfall: Urinary frequency and leakage do not exclude retention. Treatments that further impede emptying can be poorly matched to a patient whose primary problem is an overfilled bladder.
NIDDK: Definition and Facts for Bladder Control Problems · NIDDK: Treatments for Bladder Control Problems
27.When does a urethral support intervention fit the leakage mechanism?
For persistent stress leakage, a vaginal pessary can support the urethra without surgery. Sling surgery places supporting material beneath the urethra and is a reconstructive option when conservative care is insufficient. Discuss expected benefit, complications, and preferences. Urgency-predominant leakage instead favors bladder training and urgency suppression; a support operation does not address every leakage mechanism.
Apply it
Cough-triggered leakage persists despite conservative treatment. Compare a support pessary with sling surgery, including mesh-related risks if synthetic material is proposed.
Common pitfall: A urethral support procedure and treatment for urgency have different targets. Establish the symptom mechanism before recommending reconstruction.
NIDDK: Treatments for Bladder Control Problems · NIDDK: Definition and Facts for Bladder Control Problems
28.How can an applied structure-function assessment improve pelvic floor rehabilitation?
Assess whether the patient can contract the pelvic floor rather than substituting abdominal, thigh, or buttock effort. Consider the lower back, abdominal, and pelvic floor muscles together because they contribute to pelvic alignment and posture. This applies the osteopathic structure-function principle to an observable motor task. Uncertain activation supports supervised pelvic floor therapy or biofeedback before declaring training unsuccessful.
Apply it
During attempted pelvic floor contraction, a patient visibly braces her abdomen without an effective targeted contraction. Correct activation with supervised instruction before escalating treatment.
Common pitfall: Observed substitution does not prove a named somatic dysfunction or establish that manipulation will restore continence. Document the actual functional deficit and reassess it.
NIDDK: Treatments for Bladder Control Problems · AOA: Tenets of Osteopathic Medicine
Gynecologic Oncology8–12%
29.Why does persistent high-risk HPV matter more than a single infection?
Most HPV infections are controlled by the immune system and do not progress to cancer. Persistent infection with oncogenic HPV types creates the setting for cervical precancer and cancer by disrupting normal cellular growth regulation. Thus, detecting HPV is not equivalent to diagnosing malignancy, while persistent high-risk infection cannot be dismissed as interchangeable with a transient infection. Prevention combines vaccination against new infection with appropriate screening and management of abnormal findings.
Apply it
A patient interprets a positive high-risk HPV test as a cancer diagnosis. Explain the distinction among infection, persistence, precancer, and invasive disease while emphasizing why completing the recommended evaluation remains important despite that distinction.
Common pitfall: Do not equate every HPV type with the same oncogenic potential. Low-risk types associated with warts and high-risk types associated with cancer require different interpretation.
30.Which family pattern suggests Lynch syndrome?
Lynch syndrome results from inherited defects affecting DNA mismatch repair and increases susceptibility to colorectal, endometrial, and other cancers. A family containing early colorectal cancer together with endometrial cancer is therefore a meaningful hereditary clue. Tumor mismatch-repair findings can prompt further assessment, but an abnormal tumor result alone does not establish an inherited variant. The decision is to connect the cancer pattern with genetic evaluation rather than treating each organ-specific diagnosis as unrelated.
Apply it
A patient with endometrial cancer reports a parent with colorectal cancer in early adulthood and another relative with endometrial cancer. Recognize the cross-organ pattern and include hereditary mismatch-repair assessment in the cancer evaluation.
Common pitfall: Do not restrict hereditary gynecologic cancer thinking to breast and ovarian cancer. Endometrial and colorectal clustering points toward a different inherited susceptibility pathway.
31.Why is BRCA-related ovarian cancer prevention different from screening?
Pathogenic BRCA variants increase ovarian and related cancer risk. Transvaginal ultrasound and CA-125 testing have not demonstrated effective early detection that improves outcomes sufficiently to replace established risk-reduction strategies. Risk-reducing salpingo-oophorectomy removes the ovaries and fallopian tubes and can substantially reduce risk, although a residual primary peritoneal cancer risk remains. Timing depends on the specific variant, reproductive plans, and consequences of surgical menopause; salpingectomy alone is still being studied.
Apply it
A BRCA carrier who has completed childbearing asks whether annual CA-125 testing offers the same protection as risk-reducing surgery. Explain the difference between looking for disease and reducing its likelihood, including the limitations of available screening.
Common pitfall: Do not present normal screening results as assurance against future ovarian cancer. Also avoid describing salpingectomy alone as an established equivalent to salpingo-oophorectomy.
32.How do FIGO 2023 stage and tumor grade answer different questions in endometrial cancer?
Grade describes histologic differentiation; for endometrioid carcinoma, architectural grade reflects the proportion of solid growth. Anatomical extent remains central to staging, but FIGO 2023 also incorporates histologic type, lymphovascular space invasion, and selected molecular findings. For example, aggressive histology with any myometrial invasion meets stage IIC criteria before applicable molecular modification. A uterine-confined tumor therefore need not be stage I. Mismatch-repair status supplies additional molecular information but does not itself change the early FIGO stage category.
Apply it
A uterine-confined serous carcinoma invades the myometrium. Apply the FIGO 2023 aggressive-histology stage IIC criterion rather than assigning stage I solely from its anatomical confinement.
Common pitfall: Always identify the staging system. Grade remains a distinct pathological descriptor even when histology contributes to FIGO 2023 stage.
NCI: Endometrial Cancer Treatment (PDQ), Health Professional Version
33.How can mismatch-repair deficiency influence endometrial cancer treatment?
Mismatch-repair deficiency permits DNA replication errors to accumulate and often produces microsatellite instability. This molecular phenotype can help identify endometrial cancers likely to benefit from immune checkpoint inhibition in relevant advanced or recurrent treatment settings. Tumor testing therefore contributes to therapeutic selection as well as hereditary risk assessment. The important distinction is that a treatment-predictive tumor finding and a confirmed germline diagnosis answer different questions, even when they arise from the same biological pathway.
Apply it
A patient with recurrent endometrial cancer has a mismatch-repair-deficient tumor. Recognize why the result matters when considering checkpoint-based treatment options, while separately determining whether the tumor findings warrant evaluation for an inherited cancer syndrome.
Common pitfall: Do not assume mismatch-repair deficiency automatically proves Lynch syndrome. Conversely, do not dismiss tumor testing as relevant only to relatives when it may influence systemic therapy.
NCI: Endometrial Cancer Treatment (PDQ), Health Professional Version · NCI: Genetics of Breast and Gynecologic Cancers (PDQ)
34.Which treatment principle applies to operable localized endometrial cancer?
For many patients with operable localized endometrial cancer, treatment centers on hysterectomy with bilateral salpingo-oophorectomy and appropriate staging assessment. Pathological findings then help determine whether additional treatment is needed. Fertility-preserving hormonal approaches are reserved for carefully selected circumstances and require close assessment and follow-up; they are not interchangeable with standard surgery for every patient. The decision integrates disease features, operative fitness, and reproductive goals rather than choosing treatment from bleeding symptoms alone.
Apply it
A medically fit patient with localized endometrial carcinoma has completed childbearing. Discuss definitive surgical treatment and staging assessment rather than presenting radiation, chemotherapy, and hormonal therapy as routinely equivalent initial choices for her situation.
Common pitfall: A desire to avoid surgery does not itself establish eligibility for fertility-preserving treatment. Histology, disease extent, and the ability to undergo surveillance remain essential boundaries.
NCI: Endometrial Cancer Treatment (PDQ), Health Professional Version
Obstetrics and Maternal Fetal Medicine42–46%
35.When should folic acid supplementation begin before pregnancy?
The neural tube closes early in embryonic development, often before pregnancy is recognized. The USPSTF therefore recommends that people planning or capable of pregnancy take 0.4–0.8 mg of folic acid daily, beginning at least one month before conception and continuing through the first two to three months of pregnancy. This routine-risk recommendation is preventive. A history or condition conferring particularly high risk requires separate assessment rather than automatic use of the routine range.
Apply it
A patient plans to stop contraception next month and asks whether vitamins can wait until a positive pregnancy test. Recommend beginning routine folic acid now and review her history for factors requiring a different prevention plan.
Common pitfall: Do not wait for the first prenatal visit to address neural tube defect prevention. The biologically important developmental period may already have occurred by then.
USPSTF: Folic Acid Supplementation to Prevent Neural Tube Defects
36.Why screen for asymptomatic bacteriuria during pregnancy?
Asymptomatic bacteriuria means bacteria are present in urine without urinary infection symptoms. During pregnancy, identifying and treating this condition reduces the risk of pyelonephritis. The USPSTF recommends screening with a urine culture at the first prenatal visit or at 12–16 weeks, whichever occurs earlier. Culture matters because the patient has no symptoms to trigger diagnosis and a routine dipstick does not provide the same assessment of bacterial growth.
Apply it
At an initial prenatal visit, a patient denies dysuria, urgency, and fever. Explain why a screening urine culture is still indicated and why the absence of symptoms does not make the test unnecessary during pregnancy.
Common pitfall: Do not transfer the recommendation against routine screening in nonpregnant adults to pregnancy. Pregnancy changes the benefit of detecting and treating otherwise silent bacteriuria.
37.When and where is routine maternal group B streptococcal screening performed?
CDC guidance describes GBS screening during the 36th or 37th week of each pregnancy using samples from the vagina and rectum. Maternal colonization can expose the newborn during birth, and the result helps determine whether antibiotics are needed during labor. Colonization can change, so a result from a previous pregnancy does not reliably establish the current pregnancy's status. Screening is directed at carriage rather than diagnosing maternal symptoms.
Apply it
A patient at 36 weeks says she had a negative GBS result in her previous pregnancy. Arrange current vaginal and rectal screening and explain why an old negative result cannot establish her colonization status for this delivery.
Common pitfall: Do not substitute a urine dipstick or a remote pregnancy result for the indicated vaginal and rectal screen. The tests address different clinical questions.
38.Why is GBS prevention timed to labor rather than a positive swab alone?
GBS carriage is often asymptomatic, but transmission around birth can cause serious neonatal infection. For patients identified as needing prophylaxis, antibiotics during labor reduce exposure when delivery is occurring. A positive screening swab therefore guides a birth-related prevention plan rather than proving that the mother has symptomatic disease. Because carriage may recur, attempting to erase colonization well before birth does not provide the same protection as appropriately timed intrapartum prevention.
Apply it
A patient with a positive late-pregnancy GBS screen asks for medication immediately so labor antibiotics will be unnecessary. Explain the timing of neonatal exposure and document the plan for indicated antibiotics during labor.
Common pitfall: Do not confuse asymptomatic vaginal-rectal colonization with a symptomatic maternal infection. A separate urinary or systemic infection requires its own assessment and treatment plan.
39.What does the USPSTF establish about gestational diabetes screening timing?
The USPSTF recommends gestational diabetes screening in asymptomatic pregnant patients at or after 24 weeks. Identifying hyperglycemia allows treatment that improves important maternal and neonatal outcomes. For screening before 24 weeks, the USPSTF finds evidence insufficient to determine the balance of benefits and harms. That evidence statement concerns routine gestational diabetes screening; it does not prohibit diagnostic evaluation when symptoms or other findings suggest preexisting or overt diabetes.
Apply it
An asymptomatic patient at 25 weeks has not undergone gestational diabetes screening. Arrange screening now, while distinguishing this routine decision from a separate situation in which marked hyperglycemic symptoms would require immediate diagnostic investigation.
Common pitfall: Insufficient evidence for routine early screening does not mean that early symptomatic hyperglycemia should be ignored. Screening recommendations and diagnostic evaluation have different purposes.
40.Why is Tdap recommended during each pregnancy?
Tdap vaccination during pregnancy promotes maternal antibodies that cross the placenta and help protect the infant before the infant's own vaccine series can provide protection. CDC recommends administration during each pregnancy, preferably early in the 27–36-week window. The goal is timely passive newborn protection, so a dose received years earlier does not replace the pregnancy-specific recommendation. Prior vaccination history remains relevant, but it does not remove this distinct neonatal prevention objective.
Apply it
A patient at 28 weeks received Tdap three years ago and asks whether another dose is redundant. Explain transplacental antibody transfer and offer the pregnancy-recommended dose within the current window to support newborn protection.
Common pitfall: Do not use the ordinary adult booster interval to decide whether Tdap is indicated in pregnancy. The repeated pregnancy recommendation serves a separate infant-protection purpose.
41.Why is MMR deferred during pregnancy?
MMR is a live attenuated vaccine and is contraindicated during pregnancy. A pregnant patient found to lack rubella immunity should receive counseling and a plan for postpartum vaccination rather than immediate MMR. This differs from recommended nonlive vaccines such as Tdap. CDC also distinguishes inadvertent exposure from intentional administration: an accidental MMR vaccination during pregnancy is not, by itself, a reason to recommend termination of the pregnancy.
Apply it
Prenatal testing shows rubella nonimmunity. Explain why MMR is postponed until after delivery, document the postpartum vaccination plan, and distinguish that recommendation from vaccines that are specifically recommended during the current pregnancy.
Common pitfall: Do not generalize the live-vaccine restriction to all immunizations. Conversely, reassuring counseling after inadvertent MMR exposure does not make planned vaccination during pregnancy appropriate.
42.Which patients are candidates for aspirin prevention of preeclampsia?
The USPSTF recommends low-dose aspirin, 81 mg daily after 12 weeks of gestation, for pregnant patients at high risk of preeclampsia. High-risk factors include prior preeclampsia, multifetal gestation, chronic hypertension, pregestational diabetes, kidney disease, and certain autoimmune diseases. Combinations of moderate-risk factors may also support use. Aspirin is preventive rather than treatment for an established hypertensive emergency; the decision is made from risk history before the complication develops.
Apply it
At a 13-week visit, a patient reports preeclampsia in her previous pregnancy. Recognize that history as a high-risk factor and discuss preventive low-dose aspirin rather than waiting for elevated blood pressure or proteinuria to appear.
Common pitfall: Do not confuse prophylactic aspirin with acute treatment of severe hypertension or eclampsia. Those complications require their own immediate management even if aspirin was previously prescribed.
USPSTF: Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality
43.How can preeclampsia be diagnosed without proteinuria?
ACOG defines new hypertension as systolic pressure at least 140 mm Hg or diastolic pressure at least 90 mm Hg on two occasions at least four hours apart after 20 weeks in a previously normotensive patient. Without proteinuria, qualifying new findings include platelets below 100,000/µL; creatinine above 1.1 mg/dL or doubling without another renal cause; transaminases twice normal; pulmonary edema; visual symptoms; or a new headache unresponsive to medication and unexplained by another diagnosis. Headache alone is nonspecific and requires careful corroboration. Severe-range pressure, at least 160 systolic or 110 diastolic, can be confirmed within minutes to permit timely treatment.
Apply it
At 32 weeks, repeated pressures of 152/96 mm Hg and platelets of 88,000/µL without another cause establish preeclampsia with a severe feature despite absent proteinuria and pressures below the severe range.
Common pitfall: A mildly reduced platelet count or an ordinary responsive headache does not satisfy these organ-injury criteria. Proteinuria is not required when a qualifying feature is present.
Gestational_Hypertension_and_Preeclampsia_ACOG_Practice_Bulletin,_Number_222_1605448006.pdf
44.How do magnesium sulfate and antihypertensive treatment serve different purposes?
In severe preeclampsia and eclampsia care, magnesium sulfate is used to prevent or treat seizures. Antihypertensive treatment addresses dangerous blood pressure and its associated complications. These interventions have different targets and may both be needed. Lowering blood pressure does not provide equivalent seizure prophylaxis, while magnesium should not be treated as the primary blood-pressure drug. Recognizing the separate purposes prevents apparent improvement in one physiological measure from obscuring another ongoing risk.
Apply it
A patient with severe preeclampsia has improved blood pressure after antihypertensive treatment. Explain why the improvement does not automatically remove the indication for magnesium sulfate when seizure prevention remains clinically necessary in her management plan.
Common pitfall: Do not choose between seizure prevention and blood-pressure control as if they were interchangeable therapies. A patient may require both because they address different hazards.
45.Why can preeclampsia remain dangerous after delivery?
Delivery removes the placenta but does not instantly reverse the maternal vascular and organ effects of preeclampsia. Disease can persist, worsen, or first become apparent postpartum. Severe headache, visual disturbance, upper abdominal pain, breathlessness, or other concerning symptoms require assessment after birth as well as during pregnancy. The discriminating lesson is that postpartum timing does not exclude a hypertensive complication, particularly when symptoms suggest neurologic, hepatic, or pulmonary involvement.
Apply it
Several days after delivery, a patient reports a severe persistent headache and visual disturbance. Arrange urgent assessment including blood pressure rather than attributing the symptoms to sleep deprivation simply because the pregnancy has ended.
Common pitfall: Do not reassure solely on the basis of a completed delivery or a previously normal prenatal blood pressure. New postpartum symptoms can represent new-onset disease.
46.What long-term counseling follows a pregnancy complicated by preeclampsia?
A history of preeclampsia is associated with increased later cardiovascular risk, including hypertension and cardiovascular disease. Postpartum care should therefore connect the pregnancy history with ongoing primary care, blood-pressure review, and attention to modifiable cardiovascular risks. This is a risk marker rather than a prediction that disease is inevitable. The decision is to preserve the obstetric history as clinically relevant information after reproductive care ends, rather than treating resolution of pregnancy symptoms as the endpoint.
Apply it
At a follow-up visit after preeclampsia, a patient has recovered and asks whether the episode has any future relevance. Discuss cardiovascular risk and ensure that her primary care clinician receives the pregnancy history for ongoing preventive assessment.
Common pitfall: Do not frame future cardiovascular disease as certain. Counseling should explain increased risk and practical prevention without converting an association into an individual prediction.
47.Why is cell-free DNA testing a screening test rather than a diagnosis?
Cell-free DNA screening analyzes DNA fragments in maternal blood, with the pregnancy-associated signal arising largely from placental tissue. It provides highly informative screening for common aneuploidies but can produce discordant results because placental and fetal findings are not always identical. A high-risk result changes probability rather than establishing fetal disease. Counseling must distinguish sensitivity from positive predictive value and connect the result to an offer of diagnostic testing before irreversible decisions.
Apply it
A patient receives a high-risk trisomy screening result and assumes the fetus is definitely affected. Explain the placental basis and probabilistic meaning of the test, then discuss genetic counseling, ultrasound assessment, and diagnostic options.
Common pitfall: High screening sensitivity does not make every positive result true. Positive predictive value depends on the condition and prior probability as well as test performance.
48.What follows a positive cfDNA result at 16 weeks?
SMFM recommends genetic counseling, comprehensive ultrasound evaluation, and an offer of diagnostic testing after a positive cfDNA result. At 16 weeks, amniocentesis is a gestationally appropriate diagnostic procedure; RCOG guidance supports its use from 15 weeks. A normal ultrasound does not negate a positive screen because not every affected fetus has recognizable structural findings. The decision is to obtain diagnostic information when desired rather than repeating screening as if repetition could establish certainty.
Apply it
At 16 weeks, a patient has a positive cfDNA screen but a reassuring ultrasound. Explain why these results can coexist and offer diagnostic amniocentesis after counseling, aligning the next step with her preferences for diagnostic certainty.
Common pitfall: Do not use a second screening test to certify or dismiss the first positive screen. Screening repetition and diagnostic sampling provide different levels of evidence.
SMFM Consult Series #74: Full Guidance PDF · RCOG: Amniocentesis and Chorionic Villus Sampling, Green-top Guideline No. 8
49.Which fetal assessments accompany expectant care for preeclampsia without severe features?
ACOG Practice Bulletin 222 recommends growth ultrasound every 3–4 weeks, amniotic fluid assessment at least weekly, and antenatal testing once or twice weekly during expectant care. These assessments address different consequences of impaired uteroplacental perfusion: restricted fetal growth, oligohydramnios, and nonreassuring fetal status. Growth assessment follows a longitudinal pattern, whereas fluid assessment and antenatal testing provide more frequent surveillance. Maternal stability alone does not establish fetal well-being because placental dysfunction can affect the fetus even when maternal symptoms remain limited.
Apply it
At 33 weeks, a patient with stable preeclampsia without severe features needs scheduled growth assessment, weekly fluid assessment, and once- or twice-weekly antenatal testing alongside maternal monitoring. An abnormal fetal result requires reassessment of whether expectant management remains appropriate.
Common pitfall: A normal growth scan does not replace ongoing fluid assessment or antenatal testing. Conversely, one reassuring surveillance result does not guarantee that fetal condition will remain reassuring between assessments.
Gestational_Hypertension_and_Preeclampsia_ACOG_Practice_Bulletin,_Number_222_1605448006.pdf
50.Which cfDNA recommendations apply specifically to twin pregnancy?
SMFM Consult Series 74 recommends cfDNA as a first-line screening option for trisomy 21 in twins and also recommends screening for trisomies 18 and 13. It does not recommend cfDNA screening for sex chromosome aneuploidies in twins or cfDNA screening in higher-order multiples because data are insufficient. These are explicit limits on recommended use, rather than evidence that every expanded panel is suitable whenever common-trisomy screening is supported.
Apply it
A patient with twins requests an expanded panel. Explain that common-trisomy screening is supported, while sex chromosome aneuploidy screening in twins is not recommended. A triplet pregnancy falls within the separate recommendation against cfDNA screening in higher-order multiples.
Common pitfall: Do not extend the supported twin common-trisomy recommendation to sex chromosome screening or to pregnancies with three or more fetuses.
SMFM Consult Series #74: Cell-free DNA Screening for Aneuploidies—Updated Guidance (2025) · SMFM Consult Series #74: Full Guidance PDF
51.Which fetal findings change expectant-management decisions in preeclampsia?
ACOG identifies abnormal fetal testing and persistent reversed end-diastolic umbilical-artery flow as findings precluding expectant management. After maternal stabilization, these support expedited delivery. Growth restriction alone need not end observation when fluid, Doppler findings, and antenatal testing remain normal and no other delivery indication exists.
Apply it
Growth restriction with reassuring surveillance differs from growth restriction with persistent reversed flow; the latter changes the delivery decision.
Common pitfall: Do not use fetal size alone to summarize fetal condition or dismiss abnormal Doppler findings because maternal symptoms are mild.
Gestational_Hypertension_and_Preeclampsia_ACOG_Practice_Bulletin,_Number_222_1605448006.pdf
52.How does placenta previa differ from a low-lying placenta?
Placenta previa means placental tissue covers the internal cervical opening. RCOG defines a low-lying placenta as a placental edge less than 20 mm from that opening without covering it. Ultrasound measures this relationship; transvaginal ultrasound can safely clarify the location. An early low position may change as the uterus develops. Follow-up measurements, gestational age, bleeding, and the applicable guideline inform birth planning.
Apply it
A midpregnancy scan shows the placental edge 12 mm from the internal opening without coverage. Describe a low-lying placenta and arrange follow-up location assessment. Under the cited RCOG guidance, an edge remaining less than 20 mm away at 36 weeks favors cesarean birth.
Common pitfall: A midpregnancy distance does not establish the final route of birth. Attribute delivery thresholds to the guideline being applied and reassess placental location.
53.Why does previa over a cesarean scar raise concern for placenta accreta?
Placenta accreta spectrum involves abnormal placental adherence or invasion at the uterine wall. Previous cesarean delivery and placenta previa together create an important risk pattern because implantation may occur over an area of uterine scarring. Failure of normal placental separation can cause major hemorrhage. Recognizing the pattern before birth supports targeted assessment and planned multidisciplinary care, rather than discovering the problem only when attempts at placental delivery provoke uncontrolled bleeding.
Apply it
A patient with two prior cesarean deliveries has an anterior placenta previa. Recognize the combined risk pattern and arrange assessment for accreta spectrum with specialist birth planning, even if she has not yet experienced bleeding.
Common pitfall: Do not equate previa with accreta or assume every scarred uterus has invasive placentation. The combination raises suspicion and prompts assessment rather than establishing the diagnosis.
54.Why is bleeding from vasa previa especially dangerous to the fetus?
Vasa previa involves unprotected fetal blood vessels running through membranes near or over the cervical opening. If those vessels tear during labor or membrane rupture, the blood loss is fetal rather than maternal. A relatively small visible loss can therefore be catastrophic for the fetus. The discriminating pattern is bleeding associated with membrane rupture and acute fetal compromise, which requires immediate recognition rather than judging severity from maternal vital signs alone.
Apply it
After membrane rupture, vaginal bleeding begins and the fetal heart rate suddenly deteriorates while maternal blood pressure remains normal. Recognize possible fetal vessel rupture and mobilize emergency obstetric management instead of being reassured by maternal stability.
Common pitfall: Do not use normal maternal vital signs to dismiss dangerous bleeding. In vasa previa, the fetus can be losing blood while the mother's circulation remains stable.
55.How do McRoberts positioning and suprapubic pressure address shoulder dystocia?
Shoulder dystocia occurs when the fetal shoulders do not deliver with usual assistance after the head is born. McRoberts positioning flexes the maternal hips toward the abdomen to improve the mechanics of delivery, while suprapubic pressure aims to dislodge or rotate the impacted shoulder. RCOG guidance supports these early measures within a coordinated emergency response. The problem is mechanical impaction, so repeated forceful traction on the fetal head is not an appropriate substitute.
Apply it
After delivery of the head, the shoulders remain impacted. Call for help and initiate McRoberts positioning with suprapubic pressure, using coordinated maneuvers rather than escalating traction while waiting for the shoulders to release spontaneously.
Common pitfall: Do not substitute fundal pressure for suprapubic pressure. They act in different locations, and fundal pressure can worsen the impaction rather than relieve it.
RCOG: Shoulder Dystocia, Green-top Guideline No. 42, Third Edition (2026) · RCOG: Shoulder Dystocia
56.Why does episiotomy alone not resolve shoulder dystocia?
Shoulder dystocia is principally a bony impaction problem, not simply resistance from the perineal soft tissues. An episiotomy does not enlarge the maternal bony pelvis and therefore does not itself release the impacted shoulder. It may be considered when additional room is needed to perform internal maneuvers. This distinction helps select an intervention for its actual mechanical purpose, rather than assuming that a larger soft-tissue opening automatically corrects every difficult delivery.
Apply it
During shoulder dystocia, a clinician proposes episiotomy as the sole release maneuver. Explain that it may facilitate access for internal techniques but does not directly correct the shoulder's impaction against maternal bony structures.
Common pitfall: Do not make episiotomy an automatic substitute for established dystocia maneuvers. Its possible role is access for internal assistance, not correction of the bony obstruction itself.
RCOG: Shoulder Dystocia, Green-top Guideline No. 42, Third Edition (2026)
57.Why does a boggy uterus point toward atonic postpartum hemorrhage?
After placental separation, uterine muscle contraction compresses the blood vessels at the placental bed. Uterine atony means this contraction is inadequate, allowing continued hemorrhage. A soft, enlarged, or boggy uterus during heavy postpartum bleeding supports the mechanism. Immediate care includes summoning help, resuscitation, uterine massage, and measures that promote contraction while assessing other causes. Cause-directed treatment and stabilization proceed together rather than waiting for one to be completed first.
Apply it
Soon after birth, a patient has heavy bleeding and a soft enlarged uterus. Begin the hemorrhage response with resuscitation and uterine measures while reassessing placental completeness and possible injury, rather than waiting for a laboratory result before acting.
Common pitfall: Do not assume all postpartum hemorrhage is atony. Uterine tone is a useful discriminator, but trauma, retained tissue, and coagulation problems may coexist.
58.What does persistent bleeding with a firm uterus suggest?
When postpartum bleeding persists despite a well-contracted uterus, the diagnostic emphasis should broaden beyond uterine atony. Genital tract trauma, retained placental tissue, and coagulation abnormalities are important alternative or coexisting mechanisms. A firm uterus makes failure of contraction less persuasive as the sole explanation, but it does not establish a particular alternative. Reassessment must connect examination findings, placental assessment, and the bleeding pattern while continuing resuscitation and escalation when necessary.
Apply it
A patient's uterus becomes firm after initial hemorrhage treatment, yet brisk bleeding continues. Reassess for injury, retained tissue, and coagulation problems instead of repeatedly assuming that more treatment for poor uterine tone will address the entire cause.
Common pitfall: An improved uterine examination is not equivalent to hemorrhage control. Continued visible bleeding or physiological deterioration requires renewed assessment even when the presumed initial mechanism has improved.
59.How does perinatal depression differ from transient postpartum mood changes?
Brief postpartum mood changes can include tearfulness and emotional fluctuation, whereas perinatal depression involves more persistent symptoms that impair functioning and may include hopelessness, loss of interest, guilt, and difficulty caring for oneself. NIMH distinguishes the usually short-lived baby blues from more severe or prolonged illness. Symptoms lasting beyond two weeks or causing substantial impairment merit assessment. Thoughts of self-harm or harm to the infant require immediate attention regardless of symptom duration.
Apply it
Three weeks after delivery, a patient reports persistent hopelessness, loss of pleasure, and difficulty eating and sleeping even when help is available. Assess for depression and safety concerns rather than labeling the ongoing impairment as routine baby blues.
Common pitfall: Do not require a prolonged waiting period before assessing dangerous symptoms. Suicidal thinking, severe impairment, or concern for infant safety changes the urgency immediately.
60.Which postpartum psychiatric findings require emergency care?
Postpartum psychosis may present with delusions, hallucinations, mania, paranoia, or marked confusion. It is a psychiatric emergency because judgment and reality testing are impaired, creating risk to the parent and infant. NIMH identifies the need for immediate medical attention and hospitalization. The discriminating findings are psychosis and severe behavioral or cognitive disturbance, rather than ordinary fatigue or tearfulness. Safety assessment and urgent treatment take precedence over routine outpatient reassurance.
Apply it
A newly postpartum patient has slept very little, speaks rapidly, and believes the infant is controlled by supernatural forces. Arrange emergency psychiatric assessment and safe supervision rather than scheduling a standard follow-up appointment several days later.
Common pitfall: Do not categorize delusions or hallucinations as baby blues. Psychotic symptoms require emergency care even when the patient does not explicitly state an intention to cause harm.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Prioritize Obstetrics and Maternal Fetal Medicine: distinguish screening from diagnosis, identify qualifying hypertensive organ injury, interpret fetal surveillance, and connect hemorrhage findings to the correct mechanism.
- Build Gynecology decisions around pregnancy status, bleeding source, contraceptive eligibility, infection thresholds, and endometrial risk.
- Interpret infertility and amenorrhea through timing, anatomy, and hormone feedback rather than isolated laboratory values.
- Separate stress, urgency, and overflow leakage; connect pelvic floor function and urethral support to conservative and reconstructive treatment decisions.
- Identify the cancer staging system and integrate anatomy, histology, molecular findings, and inherited susceptibility while preserving their separate meanings.
- Apply osteopathic reasoning through documented movement, muscle activation, posture, and functional findings alongside evaluation of visceral disease; study the additional OMM/OPP topics in every official domain.
A practical preparation plan
1. Map the complete official scope
Read the official written outline and mark topics covered here versus topics requiring additional study. Preserve all five official domain labels and use their published ranges to guide study time.
2. Study decisions in paired contrasts
Compare conditions that share symptoms: ectopic rupture versus stable uncertain location, anovulatory bleeding versus endometrial warning signs, and stress versus urgency versus overflow leakage. Write the finding that changes the decision.
3. Practise timing-dependent interpretation
Create a timeline for infertility evaluation, progesterone sampling, prenatal screening, fetal surveillance, vaccination, and postpartum complications. For each test, identify whether it screens, diagnoses, monitors fetal condition, confirms clearance, or looks for reinfection.
4. Complete the original question set
Answer the 20 questions before reading explanations. For each error, identify the decisive cue and explain why each competing option fails in that particular case. Difficulty labels are educational estimates.
5. Expand beyond the selective guide
Use the AOBOG recommended references to fill remaining outline topics, including operative care, pelvic organ prolapse, fetal surveillance interpretation, and domain-specific OMM/OPP. Revisit missed decisions with flashcards and new clinical cases.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- AOBOG Written Exam
- AOBOG Primary Certification in Obstetrics & Gynecology
- AOBOG Oral Exam
- AOBOG Primary Written Exam References
- CDC: Summary of U.S. Medical Eligibility Criteria for Contraceptive Use, 2024
- CDC: Pelvic Inflammatory Disease
- CDC: Bacterial Vaginosis
- CDC: Chlamydial Infections
- CDC: Clinical Overview of HPV
- USPSTF: Osteoporosis to Prevent Fractures—Screening
- RCOG: Ectopic Pregnancy
- NCI: Endometrial Cancer Treatment (PDQ), Health Professional Version
- NCI: Endometrial Cancer Prevention (PDQ), Health Professional Version
- AOA: Tenets of Osteopathic Medicine
- ASRM: Fertility Evaluation of Infertile Women—Committee Opinion (2021)
- ASRM: Current Evaluation of Amenorrhea—Committee Opinion (2024)
- NIDDK: Definition and Facts for Bladder Control Problems
- NIDDK: Treatments for Bladder Control Problems
- NCI: Genetics of Breast and Gynecologic Cancers (PDQ)
- NCI: BRCA Gene Changes—Cancer Risk and Genetic Testing
- NCI: Cervical Cancer Causes, Risk Factors, and Prevention
- USPSTF: Folic Acid Supplementation to Prevent Neural Tube Defects
- USPSTF: Gestational Diabetes—Screening
- USPSTF: Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality
- RCOG: Pre-eclampsia
- RCOG: Shoulder Dystocia
- RCOG: Heavy Bleeding After Birth
- RCOG: Placenta Praevia, Placenta Accreta and Vasa Praevia
- SMFM Consult Series #74: Cell-free DNA Screening for Aneuploidies—Updated Guidance (2025)
- SMFM Consult Series #74: Full Guidance PDF
- NIMH: Perinatal Depression
- CDC: Screening for Group B Strep Bacteria
- USPSTF: Asymptomatic Bacteriuria in Adults—Screening
- CDC: Guidelines for Vaccinating Pregnant Women
- RCOG: Shoulder Dystocia, Green-top Guideline No. 42, Third Edition (2026)
- RCOG: Amniocentesis and Chorionic Villus Sampling, Green-top Guideline No. 8
- Recommendation: Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication | United States Preventive Services Taskforce
- Gestational_Hypertension_and_Preeclampsia_ACOG_Practice_Bulletin,_Number_222_1605448006.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.